Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01934894 · ClinicalTrials.gov registry record · Phase 2
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
A Phase 2 study, sponsored by SCRI Development Innovations.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01934894 is a Phase 2 study that was terminated before completion, run by SCRI Development Innovations. The registered enrollment target is 11 participants.
The verdict
NCT01934894, a Phase 2 study, was terminated before completion, sponsored by SCRI Development Innovations.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This phase II trial will combine two agents, cabazitaxel and lapatinib, to treat patients with metastatic breast cancer (MBC) which has metastasized to the brain. The first portion of the study will determine the optimal dose of the cabazitaxel/lapatinib combination to administer to patients. After determining the optimal dose, patients will continue treatment with cabazitaxel and lapatinib to assess response to treatment with these agents.
Interventions
- DRUG lapatinib
- DRUG cabazitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01934894
The ClinicalTrials.gov registry entry for NCT01934894 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lapatinib is the first listed.
NCT01934894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01934894 about?
NCT01934894 is a clinical study titled "Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases". This phase II trial will combine two agents, cabazitaxel and lapatinib, to treat patients with metastatic breast cancer (MBC) which has metastasized to the brain. The first portion of the study will determine the optimal dose of the cabazitaxel/lapatinib combination to administer to patients. After ...
What is the current status of trial NCT01934894?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2014-05. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01934894?
The interventions under investigation include: lapatinib (DRUG), cabazitaxel (DRUG).
Who is sponsoring clinical trial NCT01934894?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.